FDA Signals Path to Approve Testosterone for Menopausal Women
A recent agency workshop invited drug sponsors to collaborate on developing the first approved testosterone therapies for women, outlining key data gaps and regulatory expectations.
The US Food and Drug Administration (FDA) held a workshop signaling its willingness to work with drug sponsors on an approval pathway for testosterone therapy for menopausal women, a significant shift for a treatment currently available only through off-label use of male-indicated drugs or compounding. There is currently no FDA-approved testosterone product for women, and the agency's call to action creates a major opportunity for drug developers to address an unmet medical need and enter a new market.
Sophisticated counsel and their pharma clients should note that this development could legitimize and standardize a growing clinical practice currently fraught with risks related to inconsistent dosing, quality control, and a lack of long-term safety data. The FDA explicitly identified critical evidence gaps that any successful submission must address, including robust clinical data on long-term cardiovascular and breast cancer risks (beyond 24 months). Drug developers with relevant products in their pipelines are now on notice to engage with the agency, while clinicians should monitor for forthcoming regulatory guidance that will shape future prescribing practices and the standard of care.